Moleculin Biotech, Inc. Foreign Currency Transaction Loss, before Tax
Moleculin Biotech, Inc. (MBRX) reported Foreign Currency Transaction Loss, before Tax of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-19.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionLossBeforeTax · last filed 2020-03-19
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for the quarter ending 2018-12-31 was $17.00K.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for the quarter ending 2018-09-30 was $22.00K.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for fiscal 2018 was $40.00K.
- Moleculin Biotech, Inc. foreign currency transaction loss, before tax for fiscal 2017 was $0.00.
| Period end | Foreign Currency Transaction Loss, before Tax 3 month | Foreign Currency Transaction Loss, before Tax 6 month | Foreign Currency Transaction Loss, before Tax 9 month | Foreign Currency Transaction Loss, before Tax 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $0.00 derived: sum of 2 quarters · filed 2020-03-19 | $0.00 10-K · filed 2020-03-19 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-16 | |||
| 2018-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $39.00K derived: sum of 2 quarters · filed 2020-03-19 | $40.00K 10-K · filed 2020-03-19 | |
| 2018-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $23.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $1.00K 10-Q · filed 2019-08-16 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 10-K · filed 2019-02-21 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |